Coronavirus Notebook: ‘No Urgent Need’ For Booster Vaccines, But EU & UK Advise Additional Doses In Immunocompromised
ExeVir Bio has begun a Phase Ib study of its neutralizing antibody XVR011, NRx Pharmaceuticals has reported promising results with aviptadil in improving lung function, and Meletios Therapeutics has raised funds to further the development of an antiviral that acts on the SARS-CoV-2 virus and infected host cells.
You may also be interested in...
As the debate continues over whether booster vaccines will be required to sustain waning immune responses in the general population, the EU regulator says it should have the results of its assessment of an application for a booster dose of Cominarty in the next few weeks.
Initial results of the OCTAVE DUO study are expected later this year and will feed into the UK’s deployment of COVID-19 vaccines in people with weakened immune systems.
Coronavirus Notebook: UK OKs Moderna Vaccine For Younger People, New Study Says Pfizer & AZ Vaccines Effective Against Delta Variant
Two antibody products, one from ExeVir Bio, the other from Tiziana Life Sciences, have shown efficacy against COVID-19 in clinical trials.